

CITATION REPORT

List of articles citing

Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders

DOI: 10.1016/j.arteri.2015.11.001

Clnica E Investigacin En Arteriosclerosis, 2016, 28, 71-8.

Source: <https://exaly.com/paper-pdf/65363337/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
31	PCSK9 and diabetes: is there a link?. <i>Drug Discovery Today</i> , 2017 , 22, 883-895	8.8	25
30	Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome components among young adult females. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017 , 11 Suppl 1, S337-S341	8.9	12
29	Implications of Sortilin in Lipid Metabolism and Lipid Disorder Diseases. <i>DNA and Cell Biology</i> , 2017 , 36, 1050-1061	3.6	22
28	Association Between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and the Presence of Metabolic Syndrome in a Predominantly Rural-Based Sub-Saharan African Population. <i>Metabolic Syndrome and Related Disorders</i> , 2017 , 15, 423-429	2.6	9
27	Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol \geq 70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy. <i>Vascular Health and Risk Management</i> , 2017 , 13, 247-253	4.4	2
26	Effects of increased body weight and short-term weight loss on serum PCSK9 levels - a prospective pilot study. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2017 , 2, e46-e51	0.9	9
25	Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps. <i>Pharmacological Research</i> , 2018 , 130, 1-11	10.2	17
24	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 130-136	4.9	27
23	Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 211-218	4.9	10
22	COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018 , 11, 683-697	3.4	7
21	Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance. <i>Journal of Lipid Research</i> , 2018 , 59, 1501-1509	6.3	4
20	Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population. <i>Lipids in Health and Disease</i> , 2018 , 17, 15	4.4	6
19	Association between plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and lipids with rs7903146 polymorphisms of the TCF7L2 gene in diabetic patients. <i>International Journal of Diabetes in Developing Countries</i> , 2019 , 39, 380-386	0.8	
18	Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2019 , 4, e144-e150	0.9	4
17	Effect of Physical Activity on Plasma PCSK9 in Subjects With High Risk for Type 2 Diabetes. <i>Frontiers in Physiology</i> , 2019 , 10, 456	4.6	2
16	Proprotein convertase subtilisin/kexin type 9 and mortality in patients starting hemodialysis. <i>European Journal of Clinical Investigation</i> , 2019 , 49, e13113	4.6	4
15	A phenome-wide association study to discover pleiotropic effects of , , and. <i>Npj Genomic Medicine</i> , 2019 , 4, 3	6.2	14

14	Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes. <i>Atherosclerosis</i> , 2020 , 293, 49-56	3.1	9
13	Combined intake of glucose-and lipid-lowering medications further elevates plasma levels of PCSK9 in type 2 diabetes patients. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020 , 14, 2087-2092	8.9	2
12	PCSK9: Associated with cardiac diseases and their risk factors?. <i>Archives of Biochemistry and Biophysics</i> , 2021 , 704, 108717	4.1	5
11	PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different Glucose Tolerance under Statin Therapy. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	0
10	Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021 , 28, 329-337	4	4
9	Rescue effect of sodium acetate in diabetes mellitus-associated testicular dysfunction is accompanied by PCSK9 modulation. <i>Biochimie</i> , 2021 , 184, 52-62	4.6	5
8	Association between the rs615563 variant of PCSK9 gene and circulating lipids and Type 2 diabetes. <i>BMC Research Notes</i> , 2021 , 14, 309	2.3	1
7	Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 943-953	6.7	9
6	Insight into the Evolving Role of PCSK9.. <i>Metabolites</i> , 2022 , 12,	5.6	3
5	Correlation Between Circulating PCSK9 Levels and Gestational Diabetes Mellitus in a Chinese Population.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 826757	5.7	
4	Image_1.pdf. 2019 ,		
3	PCSK9 and Other Metabolic Targets to Counteract Ischemia/Reperfusion Injury in Acute Myocardial Infarction and Visceral Vascular Surgery. <i>Journal of Clinical Medicine</i> , 2022 , 11, 3638	5.1	0
2	Molecular and cellular biology of PCSK9: impact on glucose homeostasis. <i>Journal of Drug Targeting</i> , 1-29	5.4	1
1	Application of <i>Caenorhabditis elegans</i> in the evaluation of food nutrition: A review. 2023 , 4,		0